中国肺癌杂志2016，Vol.19Issue(5)：263-268,6.DOI:10.3779/j.issn.1009-3419.2016.05.03
西妥昔单抗联合化疗治疗晚期非小细胞肺癌的临床疗效分析
Efifcacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer
摘要
Abstract
Background and objective Cetuximab is a monoclonal antibody directed against epidermal growth fac-tor receptor. Emerging evidence showed improved effcacy with the addition of cetuximab to chemotherapy in advanced non-small cell lung cancer (NSCLC), but the data in oriental population are limited. hTe aim of this study is to investigate the eff-cacy of cetuximab in combination with chemotherapy in Chinese patients with advanced NSCLC.Methods NSCLC patients receiving cetuximab in combination with chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College were enrolled and retrospectively analyzed. Clinical characteristic, effcacy, outcome and toxicity data were analyzed.Results A total of 40 patients were enrolled into this study in which 29 were male, 36 with adenocarcinoma. In the 23 patients who had received palliative chemotherapy previously (with a median of 2 prior chemotherapy regimens), the median progression-free survival (PFS) atfer the last prior chemotherapy regimen was 2.3 months. For the overall population, 13 (32.5%) patients achieved partial response atfer cetuximab in combination with chemotherapy. Response rate were 52.9% (9/17) and 17.4% (4/23) in chemotherapy-naive patients and chemotherapy-treated patients, respectively (P=0.018). hTe median PFS was 4.8 months for the overall population. In chemotherapy-naive patients and chemotherapy-treated patients, the median PFS was 8.4 months and 4.1 months, respectively (P=0.062). hTe estimated median overall survival was 17.1 months. Toxicities were generally manageable and no treatment-related deaths occurred.Conclusion Cetuximab in addition to che-motherapy appears to be associated with promising effcacy and acceptable toxicity proifle in Chinese patients with advanced NSCLC. Further validation is needed.关键词
肺肿瘤/西妥昔单抗/靶向治疗/化疗Key words
Lung neoplasms/Cetuximab/Targeted therapy/Chemotherapy引用本文复制引用
杨晟,赵龙妹,姜培娣,屈凤莲,张湘茹,石远凯,王燕,胡兴胜,王宏羽,郝学志,许建萍,汪麟,王彬,李峻岭..西妥昔单抗联合化疗治疗晚期非小细胞肺癌的临床疗效分析[J].中国肺癌杂志,2016,19(5):263-268,6.基金项目
本研究受重大新药创制（No.2008ZX09312, No.2012ZX09303012-001）和国家科技支撑计划（No.2014BAI09B01）资助@@@@This study was supported by the grants from National Major Scientiifc and Technological Special Project for Signiif-cant New Drugs Development (to Yuankai SHI)(No.2008ZX09312, No.2012ZX09303012-001) and the National Key Tech-nology Support Program (to Sheng YANG)(No.2014BAI09B01) （to Yuankai SHI）
